# US Biomarkers Advanced Technologies Market

> United States Biomarkers Advanced Technologies Market Research Report Information By Application (Risk Assessment, Development of Molecular Diagnostics, Disease Diagnosis, Drug Discovery and Development, Drug Formulation, Forensic Application, Others (DNA fingerprinting and others)), By Indication (Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Other Disease Indications), By End User (Pharmaceutical and Biotechnology Companies, Diagnostics and Research Laboratories, Hospitals, Specialty Clinics, Others)– United States Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.81%
- **2024:** $ 1.53 Billion
- **2025:** $ 1.61 Billion
- **2035:** $ 2.56 Billion
- **Key Players:** Thermo Fisher Scientific (US), Roche Diagnostics (US), Abbott Laboratories (US), Illumina (US), Agilent Technologies (US), Bio-Rad Laboratories (US), PerkinElmer (US), Qiagen (US), Merck KGaA (US), SAB Biotherapeutics (US)

**Report ID:** MRFR/HC/20202-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biomarkers-advanced-technologies-market-21800

---

## Market Summary

## **United States Biomarkers Advanced Technologies Market Overview**

United States Biomarkers Advanced Technologies Market Size was valued at USD 63.1 Billion in 2023. The United States Biomarkers Advanced Technologies market industry is projected to grow from USD 70.55 Billion in 2024 to USD 159.69 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.50% during the forecast period (2023 - 2032). Increasing acceptance of precision medicine initiatives and a growing demand for non-invasive or minimally invasive testing methods are the main market drivers anticipated to propel the United States Biomarkers Advanced Technologies market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **United States Biomarkers Advanced Technologies Market Trends**

The market CAGR for United States biomarkers advanced technologiesis anticipated to be driven by rising investments in biomarker research & development, strategic alliances, and new product introductions. Notable partnerships, like the one between Personal is, Inc. and Merck KGaA, are centered on using Personal is' cutting-edge cancer immunogenomics platform, ImmunoID NeXT, to find novel biomarkers linked to cancer drug response and resistance mechanisms. Regulatory procedures are often stringent when integrating biomarker-based diagnostics into clinical practice in United States. The particular method will vary depending on whether the biomarker is to be used for prognostic, predictive, or diagnostic purposes.

The United States' Food and Drug Administration (FDA) is in charge of regulating the approval process, however other nations have their own regulatory bodies.

Furthermore, customizing treatment plans according to a patient's unique genetic composition and abnormal characteristics is made possible in large part by biomarkers. The ongoing advancements in proteomics and genomes research will soon lead to the widespread discovery of distinct biomarkers for targeted healing processes. Enhancing treatment efficacy is optimal, but it also lessens side effects, which raises the need for biomarker-pushed diagnostics in United States. The field of medical research is changing rapidly due to the incorporation of biomarkers into clinical trials.

Biomarkers provide valuable tools for the development of new medications by providing insights into the biology of diseases, the efficacy of treatments, and the classification of patients in United States. Biomarkers are being used by pharmaceutical companies more and more to speed up the development of new drugs. The product, As per the March 2022 report from the World Health Organization, 17.9 million deaths globally are attributed to cardiovascular illnesses annually. This amounts to 35% of all deaths worldwide. Moreover, heart attacks and strokes are the cause of 85% of cardiovascular disease-related fatalities.

As per a July 2020 Cureus Journal of Medical Science article, Ischemic heart disease (IHD) is one of the primary causes of death globally.

## **United States Biomarkers Advanced Technologies Market Segment Insights**

The United States Biomarkers Advanced Technologies market segmentation, based on application includes Risk Assessment, Development of Molecular Diagnostics, Disease Diagnosis, Drug Discovery and Development, Drug Formulation, Forensic Application, and Others (DNA fingerprinting and others). The development of molecular diagnostics segment dominated the market mostly. Because of its benefits in early-stage disease detection—especially for COVID-19—rapid growth is anticipated. This demand is also fueled by rising disposable income and hospital capacity growth.

The United States Biomarkers Advanced Technologies market segmentation, based on Indication, includes Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, and Other disease indications. The cancer segment generated the most income. Within the indication type, the cancer biomarkers industry is flourishing. Large producers in the industry are expected to contribute to a strong product pipeline that will further strengthen this industry. The need for biomarkers is also being driven by an increase in cancer diagnoses and an aging population.

The United States Biomarkers Advanced Technologies market segmentation, based on End User, includes Pharmaceutical and Biotechnology Companies, Diagnostics and Research Laboratories, Hospitals, Specialty Clinics, and Others. The pharmaceutical and Biotechnology Companies generated the most income. Significant financial investments and assistance from the public and corporate sectors are advancing the development of biomarkers. For instance, Empire Genomics, LLC offers sizeable funding to support scientists and physicians in developing and confirming new biomarkers in oncology.

**Figure 1: United States Biomarkers Advanced Technologies Market, by End user, 2022 & 2032 (USD Billion)**

****

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **United States Biomarkers Advanced Technologies Country Insights**

Major health concerns in the United States are chronic diseases, which include cancer, cardiovascular disease, diabetes, and neurological disorders. Advanced biomarker technologies are in high demand because biomarkers are essential for the early diagnosis, monitoring, and detection of various illnesses. The United States government, pharmaceutical firms, and individual investors are making significant investments in biomarker technology research and development. The development, validation, and commercialization of biomarkers for use in drug research, patient monitoring, and illness diagnosis are all supported by this funding in the united states. Patients and healthcare professionals are increasingly favoring non-invasive or minimally invasive diagnostic methods.

Less intrusive alternatives to conventional diagnostic techniques are provided by biomarker-based diagnostic instruments, which enhance patient compliance and comfort.

## **United States Biomarkers Advanced Technologies Key Market Players & Competitive Insights**

Leading market players are making significant investments in R&D to broaden their product offerings, which will encourage further growth in the United States Biomarkers Advanced Technologies sector. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including releases of new products, contracts, acquisitions and mergers, increased investments, and cooperation with other enterprises. To grow and endure in a market that is becoming more and more competitive, the United States Biomarkers Advanced Technologies industry must provide reasonably priced goods.

Major players in the United States Biomarkers Advanced Technologies market are making investments in R&D operations in an effort to boost market demand, including Abbott, Qiagen, Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthcare Private Limited, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Johnson & Johnson Services, Inc.

### **Key Companies in the United States Biomarkers Advanced Technologies market include**

## **United States Biomarkers Advanced Technologies Industry Developments**

**February 2022:**In order to determine the most effective blood tests for measuring a protein that is crucial for the early detection of rare neurodegenerative diseases, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium launched a new project titled "Neurofilament as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)".

**February 2022:**The OncoDEEP kit was introduced by the genomic and therapeutic business OncoDNA. With the use of this kit, labs equipped with NGS capabilities may conduct thorough biomarker testing, give reliable data analysis, and help oncologists treat cancer patients in the most efficient and customized ways possible.

## **United States Biomarkers Advanced Technologies Market Segmentation**

### **United States Biomarkers Advanced Technologies Application Outlook**

### **United States Biomarkers Advanced Technologies Indication Outlook**

### **United States Biomarkers Advanced Technologies End User Outlook**

## Market Drivers

### Regulatory Framework Enhancements

The regulatory landscape surrounding the US [Biomarkers Advanced Technologies](https://www.marketresearchfuture.com/reports/biomarkers-advanced-technologies-market-66046) Market is evolving, with enhancements aimed at expediting the approval process for new biomarker-based diagnostics. The Food and Drug Administration (FDA) has introduced initiatives to streamline the review of biomarker applications, thereby encouraging innovation. For instance, the FDA's Biomarker Qualification Program allows for the assessment of biomarkers in drug development, which could significantly reduce the time to market for new diagnostic tools. This supportive regulatory environment is likely to attract more companies to invest in biomarker research and development, fostering competition and innovation. As regulatory pathways become clearer and more efficient, the market is expected to expand, providing patients with access to cutting-edge diagnostic solutions.

### Advancements in Genomic Technologies

The US Biomarkers Advanced Technologies Market is significantly influenced by rapid advancements in genomic technologies. Innovations in next-generation sequencing (NGS) and CRISPR gene editing are revolutionizing the way biomarkers are identified and utilized in clinical settings. The market for NGS alone is projected to reach USD 10 billion by 2026, driven by its applications in personalized medicine and targeted therapies. These technologies enable researchers to analyze vast amounts of genetic data, facilitating the discovery of novel biomarkers that can predict disease susceptibility and treatment response. As the cost of genomic sequencing continues to decline, more healthcare institutions are likely to adopt these technologies, thereby propelling the growth of the biomarkers market. This trend underscores the importance of integrating cutting-edge genomic tools into the biomarker discovery process.

### Rising Awareness of Precision Medicine

The growing awareness of precision medicine is a pivotal driver for the US Biomarkers Advanced Technologies Market. As healthcare shifts towards more personalized approaches, the role of biomarkers in tailoring treatments to individual patients becomes increasingly critical. Educational campaigns and initiatives by healthcare organizations are enhancing public understanding of the benefits of precision medicine, which is projected to reach a market size of USD 100 billion by 2026. This shift is prompting healthcare providers to adopt biomarker testing as a standard practice, thereby increasing demand for advanced technologies that facilitate such testing. The emphasis on individualized treatment plans is likely to propel the growth of the biomarkers market, as stakeholders recognize the value of integrating biomarker data into clinical decision-making.

### Growing Demand for Early Disease Detection

The US Biomarkers Advanced Technologies Market is experiencing a notable surge in demand for early disease detection methods. This trend is largely driven by an increasing prevalence of chronic diseases, such as cancer and diabetes, which necessitate timely diagnosis for effective treatment. According to the National Cancer Institute, approximately 1.9 million new cancer cases are expected in the US in 2026, highlighting the urgent need for advanced diagnostic tools. Biomarkers play a crucial role in identifying disease at its nascent stages, thereby improving patient outcomes. The integration of advanced technologies, such as liquid biopsies and genomic profiling, is expected to enhance the accuracy and efficiency of these diagnostic processes. Consequently, the market is likely to expand as healthcare providers and patients alike prioritize early detection strategies.

### Increased Investment in Research and Development

Investment in research and development (R&D) within the US Biomarkers Advanced Technologies Market is on the rise, reflecting a commitment to innovation and improved healthcare outcomes. Government funding, alongside private sector investments, is fostering an environment conducive to biomarker research. The National Institutes of Health (NIH) allocated over USD 41 billion for biomedical research in 2025, a portion of which is directed towards biomarker studies. This influx of capital is likely to accelerate the development of novel biomarkers and associated technologies, enhancing diagnostic capabilities and therapeutic strategies. Furthermore, collaborations between academic institutions and biotechnology firms are becoming increasingly common, facilitating knowledge transfer and resource sharing. As a result, the market is poised for substantial growth, driven by a robust pipeline of innovative biomarker technologies.

## Future Outlook

The US Biomarkers Advanced Technologies Market is projected to grow at a 4.81% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for personalized medicine.

**New opportunities:**

- Development of AI-driven biomarker discovery platforms
- Expansion of liquid biopsy technologies for early disease detection
- Integration of biomarkers in companion diagnostics for targeted therapies

By 2035, the market is expected to be robust, reflecting substantial advancements and strategic growth.

## Segment Insights

### By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing)

The US Biomarkers Advanced Technologies Market showcases a diverse range of applications with oncology commanding the largest share due to its critical role in cancer diagnostics and treatment. Following oncology, cardiology is gaining momentum, reflecting the increasing prevalence of cardiovascular diseases and the demand for innovative biomarker solutions. Other applications such as neurology, infectious diseases, and metabolic disorders contribute notably; however, they trail behind in market share metrics significantly compared to these leading segments.

Oncology (Dominant) vs. Cardiology (Emerging)

Oncology remains the dominant segment within the US Biomarkers Advanced Technologies Market, characterized by robust demand for diagnostic and predictive markers that aid in personalized treatment approaches for cancer. This segment benefits from constant technological advancements and a heightened focus on cancer research. In contrast, cardiology stands out as an emerging segment driven by a surge in awareness around heart health and innovative biomarker applications aimed at early detection and management of cardiac conditions. The interplay of increased investment in research and public health initiatives propels cardiology's growth, signaling its potential to become a larger player in the near future.

### By Technology: Genomics (Largest) vs. Proteomics (Fastest-Growing)

In the US Biomarkers Advanced Technologies Market, the technology segment is primarily dominated by genomics, which captures a significant share of the market. It leverages advancements in sequencing technologies and personalized medicine, creating vast applications in therapeutic areas. Proteomics follows closely, experiencing rapid growth due to increased demand for biomarker discovery and validation in various diseases, including cancer and metabolic disorders. This market share distribution highlights the pivotal role of genomics and the accelerating interest in proteomic technologies.

Technology: Genomics (Dominant) vs. Proteomics (Emerging)

Genomics stands out as the dominant technology in the US Biomarkers Advanced Technologies Market, leveraging its ability to provide comprehensive insights into genetic variations and their implications on health. It plays a crucial role in personalized medicine, enabling tailored therapeutic interventions. On the other hand, proteomics, while emerging, is gaining traction due to its potential to reveal protein expressions and modifications associated with diseases. It is particularly favored in biomarker identification, driving innovation in diagnostics and drug development. The interplay between these technologies signifies an evolving landscape where combined insights can lead to improved clinical outcomes.

### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

In the US Biomarkers Advanced Technologies Market, Pharmaceutical Companies hold the largest share, driven by their vast investment in drug development and personalized medicine. This segment benefits from the increasing need for effective biomarkers to enhance drug efficacy and reduce time in clinical trials. On the other hand, Research Institutions are rapidly gaining traction, focusing on innovative biomarker research and collaborations with pharmaceutical companies, which contributes to their growing prominence in the market.

Pharmaceutical Companies (Dominant) vs. Research Institutions (Emerging)

Pharmaceutical Companies dominate the US Biomarkers Advanced Technologies Market due to their established processes in drug development and extensive funding capabilities. Their primary focus is on identifying biomarkers that can aid in efficient drug discovery and patient stratification. In contrast, Research Institutions, though emerging, are pivotal in academic and clinical studies, often acting as the backbone of innovation and technology transfer. They are exploring novel biomarkers driven by scientific advancements and have increasingly formed partnerships with the pharmaceutical sector to co-develop solutions. This synergy is vital for propelling future growth and research in biomarker utilization.

## Competitive Benchmarking

The Biomarkers Advanced Technologies Market is characterized by a dynamic competitive landscape, driven by rapid advancements in technology and increasing demand for personalized medicine. Key players such as Thermo Fisher Scientific (US), Roche Diagnostics (US), and Illumina (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, while Roche Diagnostics (US) emphasizes strategic collaborations to enhance its diagnostic capabilities. Illumina (US) is heavily investing in next-generation sequencing technologies, which positions it as a leader in genomic analysis. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and collaborative growth.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation and improves customer offerings.

In December 2025, Thermo Fisher Scientific (US) announced the launch of a new biomarker discovery platform aimed at accelerating drug development processes. This strategic move is likely to enhance its competitive edge by providing researchers with advanced tools for identifying and validating biomarkers, thereby streamlining the path to market for new therapeutics. The introduction of this platform underscores the company's commitment to innovation and its role in shaping the future of biomarker research.

In November 2025, Roche Diagnostics (US) expanded its partnership with a leading biotechnology firm to develop novel diagnostic solutions for oncology. This collaboration is significant as it not only enhances Roche's diagnostic capabilities but also aligns with the growing trend towards personalized medicine. By integrating advanced [biomarker technologies](https://www.marketresearchfuture.com/reports/biomarker-technologies-market-6150) into its offerings, Roche is positioning itself to meet the evolving needs of healthcare providers and patients alike.

In October 2025, Illumina (US) unveiled a new AI-driven analytics tool designed to improve the interpretation of genomic data. This tool is expected to revolutionize how clinicians utilize genomic information in patient care, thereby reinforcing Illumina's leadership in the genomics space. The integration of AI into their product offerings reflects a broader trend within the industry towards leveraging technology to enhance diagnostic accuracy and patient outcomes.

As of January 2026, the competitive trends in the Biomarkers Advanced Technologies Market are increasingly defined by digitalization, sustainability, and the integration of AI. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive landscape is shifting from traditional price-based competition to a focus on technological differentiation and supply chain reliability. This evolution suggests that future competitive advantages will hinge on the ability to innovate and adapt to changing market demands.

## Recent News & Developments

**February 2022:**In order to determine the most effective blood tests for measuring a protein that is crucial for the early detection of rare neurodegenerative diseases, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium launched a new project titled "Neurofilament as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)".

**February 2022:**The OncoDEEP kit was introduced by the genomic and therapeutic business OncoDNA. With the use of this kit, labs equipped with NGS capabilities may conduct thorough biomarker testing, give reliable data analysis, and help oncologists treat cancer patients in the most efficient and customized ways possible.

## Report Scope

| MARKET SIZE 2024 | 1.53(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.61(USD Billion) |
| MARKET SIZE 2035 | 2.56(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.81% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Roche Diagnostics (US), Abbott Laboratories (US), Illumina (US), Agilent Technologies (US), Bio-Rad Laboratories (US), PerkinElmer (US), Qiagen (US), Merck KGaA (US), SAB Biotherapeutics (US) |
| Segments Covered | Application, Technology, End Use |
| Key Market Opportunities | Integration of artificial intelligence in biomarker discovery enhances precision medicine capabilities in the US Biomarkers Advanced Technologies Market. |
| Key Market Dynamics | Technological advancements drive innovation in the US Biomarkers Advanced Technologies Market, enhancing diagnostic and therapeutic capabilities. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US Biomarkers Advanced Technologies Market?**
A: As of 2024, the market valuation was 1.53 USD Billion.

**Q: What is the projected market size for the US Biomarkers Advanced Technologies Market by 2035?**
A: The market is projected to reach 2.56 USD Billion by 2035.

**Q: What is the expected CAGR for the US Biomarkers Advanced Technologies Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 4.81%.

**Q: Which application segments are leading in the US Biomarkers Advanced Technologies Market?**
A: The leading application segments include Oncology, Cardiology, and Neurology, with valuations of 0.99, 0.61, and 0.43 USD Billion respectively.

**Q: What technologies are driving growth in the US Biomarkers Advanced Technologies Market?**
A: Key technologies include Genomics, Proteomics, and Immunoassays, with projected valuations of 0.75, 0.6, and 0.5 USD Billion respectively.

**Q: Who are the key players in the US Biomarkers Advanced Technologies Market?**
A: Key players include Thermo Fisher Scientific, Roche Diagnostics, and Abbott Laboratories, among others.

**Q: What are the primary end-use segments in the US Biomarkers Advanced Technologies Market?**
A: Primary end-use segments include Pharmaceutical Companies and Research Institutions, with valuations of 1.02 and 0.52 USD Billion respectively.

**Q: How does the market for Infectious Diseases compare to other application segments?**
A: The market for Infectious Diseases was valued at 0.24 USD Billion, which is lower than segments like Oncology and Cardiology.

**Q: What is the market valuation for Bioinformatics technology in the US Biomarkers Advanced Technologies Market?**
A: The market valuation for Bioinformatics technology is projected to be 0.31 USD Billion.

**Q: What trends are influencing the growth of the US Biomarkers Advanced Technologies Market?**
A: Trends such as advancements in genomics and proteomics technologies appear to be influencing market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biomarkers-advanced-technologies-market-21800*